Renalytix Plc Revenue Growth Rates (RNLX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Renalytix Plc  (RNLX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

RNLX's Revenue Growth by Quarter and Year

Renalytix Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RNLX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 0.52
FY 0.52





RNLX Revenue first quarter 2025 Y/Y Growth Comment
Renalytix Plc reported Revenue increase of 13.48% year on year in the first quarter 2025, to $ 0.52 millions, this is lower than Renalytix Plc's recent average Revenue rise of 99.2%.

Looking into first quarter 2025 results within Medical Laboratories industry 24 other companies have achieved higher Revenue growth. While Renalytix Plc' s Revenue growth of 13.48% ranks overall at the positon no. 2876 in the first quarter 2025.


RNLX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter June - -82.65 % - -
3rd Quarter March - -25 % -11.11 % 30.65 %
2nd Quarter December - -40.34 % 40 % -
1st Quarter September 13.48 % -52.58 % 102.08 % -
FY   - -63.38 % 193.46 % -

Financial Statements
Renalytix Plc's first quarter 2025 Revenue $ 0.52 millions RNLX's Income Statement
Renalytix Plc's first quarter 2024 Revenue $ 0.46 millions Quarterly RNLX's Income Statement


RNLX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter June - 9.26 % 372.22 % -
3rd Quarter March - -23.94 % -39.5 % -4.71 %
2nd Quarter December - 54.35 % 22.68 % 77.08 %
1st Quarter September -11.53 % -86.47 % - 20 %
FY (Year on Year)   - -63.38 % 193.46 % -


Back to RNLX Growth rate Comparisons >> Back to RNLX Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #25
Healthcare Sector #417
Overall #2876

Revenue Y/Y Growth Statistics
High Average Low
99.2 % 99.2 % 99.2 %
(Jun 30 2022)  
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #25
Healthcare Sector #417
Overall #2876
Revenue Y/Y Growth Statistics
High Average Low
99.2 % 99.2 % 99.2 %
(Jun 30 2022)  

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Renalytix Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
370.03 % 24.3 % -100 %
(Jun 30 2023)  


RNLX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Renalytix Plc disclosed drop in Revenue from the fourth quarter by -11.53% to $ 0.52 millions, from $ 0.59 millions achived in the previous reporting period.

But that's not important problem, as Renalytix Plc's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Renalytix Plc's Revenue growth quarter on quarter, overall rank is 3752.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #34
Healthcare Sector #553
Overall #3752
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #34
Healthcare Sector #553
Overall #3752
Revenue Q/Q Growth Statistics
High Average Low
370.03 % 24.3 % -100 %
(Jun 30 2023)  


RNLX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Renalytix Plc disclosed drop in Revenue from the fourth quarter by -11.53% to $ 0.52 millions, from $ 0.59 millions achived in the previous reporting period.

But that's not important problem, as Renalytix Plc's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 33 other companies have achieved higher Revenue quarter on quarter growth. While Renalytix Plc's Revenue growth quarter on quarter, overall rank is 3752.


Renalytix Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 2.35 $ 2.29 $ 5.11 $ 5.30 $ 5.78
Y / Y Revenue Growth (TTM) -59.29 % -63.6 % - - -
Year on Year Revenue Growth Overall Ranking # 3894 # 0 # 0 # 0 # 245
Seqeuential Revenue Change (TTM) 2.75 % -55.17 % -3.57 % -8.36 % -8.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 3355 # 3262 # 0 # 0 # 205


Cumulative Revenue growth Comment
Renalytix Plc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2024. If the fiscal year would end in Sep 30 2024, Renalytix Plc's annual Revenue decrease would be -59.29% year on year to $2 millions.

In the Healthcare sector 561 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3894.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 562
Overall # 3894

Revenue TTM Y/Y Growth Statistics
High Average Low
26.6 %
 -32.1 %
-63.6 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 479
S&P 500 # 3355
Cumulative Revenue growth Comment
Renalytix Plc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2024. If the fiscal year would end in Sep 30 2024, Renalytix Plc's annual Revenue drop would be -59.29% year on year to $2 millions.

In the Healthcare sector 561 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3894.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 562
Overall # 3894

Revenue TTM Y/Y Growth Statistics
High Average Low
26.6 %
-32.1 %
-63.6 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 479
S&P 500 # 3355




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RNLX's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Caredx Inc 23.35%$ 23.352 millions
Amgen Inc 23.18%$ 23.178 millions
Talkspace Inc 23.18%$ 23.176 millions
United Therapeutics Corporation22.89%$ 22.891 millions
Vanda Pharmaceuticals Inc 22.76%$ 22.764 millions
Cytokinetics Incorporated22.49%$ 22.487 millions
Adaptive Biotechnologies Corporation22.46%$ 22.458 millions
Novo Nordisk A22.44%$ 22.442 millions
Evolus Inc 22.12%$ 22.124 millions
Milestone Scientific Inc 22.07%$ 22.072 millions
Novocure Limited21.81%$ 21.814 millions
The Oncology Institute Inc 21.78%$ 21.779 millions
Rockwell Medical inc 21.71%$ 21.709 millions
Alpha Teknova Inc 21.65%$ 21.654 millions
Ascendis Pharma A21.54%$ 21.535 millions
Inari Medical Inc 21.17%$ 21.173 millions
Agios Pharmaceuticals Inc 21.15%$ 21.152 millions
Whitehawk Therapeutics Inc 21.03%$ 21.027 millions
Enovis Corp20.98%$ 20.983 millions
Liquidia Corporation20.94%$ 20.935 millions
Clearside Biomedical Inc 20.84%$ 20.838 millions
Urogen Pharma Ltd 20.82%$ 20.825 millions
Eli Lilly And Company20.43%$ 20.429 millions
Veracyte Inc 19.87%$ 19.867 millions
Viridian Therapeutics Inc 19.44%$ 19.444 millions
Agilon Health Inc 19.35%$ 19.353 millions
Boston Scientific Corporation19.34%$ 19.337 millions
Electromed Inc 19.02%$ 19.020 millions
Lifestance Health Group Inc 18.95%$ 18.953 millions
Surmodics Inc 18.80%$ 18.795 millions


About Renalytix Plc Revenue Growth Rates (RNLX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Renalytix Plc (CIK 1811115).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-128687
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Renalytix Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.